Human Immunodeficiency Virus Infections Clinical Trial
Official title:
A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius
ABX464 is a first in class that showed efficacy as an anti-HIV therapy. The present study is
intended to assess the safety, the tolerability, and pharmacokinetic parameters and to
evaluate the effect on viral load of repeated oral administrations of ABX464 in patients
infected by HIV, not previously treated for their HIV.
Two types of design are intended in this protocol: dosing every 3 days or dosing every day.
The goal is to determine the best dosing regimen to reduce viral load and minimize adverse
events.
n/a
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03563742 -
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
|
Phase 3 | |
| Completed |
NCT00294918 -
An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT00888446 -
Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
|
Phase 2 | |
| Completed |
NCT00262522 -
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
|
Phase 3 | |
| Completed |
NCT00294164 -
Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00332306 -
Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment
|
Phase 3 | |
| Completed |
NCT00727597 -
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
|
Phase 3 | |
| Active, not recruiting |
NCT00376012 -
Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis
|
Phase 3 | |
| Completed |
NCT00358917 -
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
|
Phase 3 | |
| Completed |
NCT00749840 -
Attitudes and Beliefs and the Steps of HIV Care
|
N/A |